Genetic approach provides new insight into trastuzumab resistance in breast cancer
A new study provides important insight into the mechanisms involved in resistance to treatment of breast cancer patients with trastuzumab
(Herceptin). The research, published by Cell Press in the October issue of the journal Cancer Cell , identifies markers that may help to identify patients who ...
Study Confirms Benefits of Chemo, Trastuzumab Combo to Battle Breast Cancer
The meta-analysis of five major breast cancer trials has confirmed that a combination therapy of chemotherapy and antibody trastuzumab
chemotherapy improves survival in women with operable HER-2 positive breast cancer.
Issa Dahabreh from the University of Athens conducted the meta-analysis...
St. Gallen consensus 2009: A radically different approach to treating early breast cancer
...ow evidence of any detectable oestrogen receptor. Anti-HER2 therapy such as trastuzumab
(Herceptin) is recommended for almost all patients with HER2-positive disea...ple-negative disease and conventionally is used before or concurrently with trastuzumab
for patients with HER2 positive disease, while its use is less clear-cut fo...
Immune-Based Lymphoma Treatment Shows Promise
...rence between the two groups. That's a really long time for metastatic melanoma."
Also at the meeting, researchers showed for the first time that trastuzumab
(Herceptin) -- a highly targeted biological drug widely used to treat certain kinds of breast cancer -- may also effective in patients with advanced ...
Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
...er Center researchers report that a combination of trastuzumab
and neratinib (HKI-272) a novel small molecule inh...atic breast cancer who have progressed on previous trastuzumab
based therapies. More than one-quarter of the wom...g of the American Society of Clinical Oncology.
is standard therapy for women with HER2-positive m...
Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
...Newswire/ -- Combining two chemotherapy drugs with trastuzumab
(Herceptin) to treat women who have metastatic HER...ng a combination of capecitabine, vinorelbine, and trastuzumab
offers a treatment option that is at least as bene...er that has spread -- paclitaxel or docetaxel with trastuzumab
-- always causes hair loss, Dr. Tan says.
Triple drug combination is promising option to treat metastatic HER2+ breast cancer
... ORLANDO Combining two chemotherapy drugs with trastuzumab
(Herceptin) to treat women who have metastatic HER...ng a combination of capecitabine, vinorelbine, and trastuzumab
offers a treatment option that is at least as bene...ncer that has spread paclitaxel or docetaxel with trastuzumab
always causes hair loss, Dr. Tan says.
All of ...
Drug May Help Against Inflammatory Breast Cancer
...sponded to lapatinib after previous treatment with trastuzumab
14 months for those who responded to lapatinib and had no previous trastuzumab
8.4 months for those unresponsive to lapatinib who had previously taken trastuzumab
8.2 months for those unresponsive to lapatinib w...
Milliman Care Guidelines(R) 2009 Release Emphasizes Efficiency, Quality Solutions
Expanded Authorization Guidelines - Among 42 new Ambulatory Care guidelines are three cancer chemotherapy agents, including trastuzumab
(Herceptin(R)); five genetic medicine guidelines, including BRCA testing; assisted reproductive technology; three shoulder surgery guidelines, includi...
If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
...r: Oncologists Are Eager for Improvements in Overall Survival Compared with trastuzumab
in the Metastatic Setting also finds that Genentech/Roche/Chugai's pertuzu...r: Oncologists are Eager for Improvements in Overall Survival Compared with trastuzumab
in the Metastatic Setting is a DecisionBase 2009 report. DecisionBase 20...
Trastuzumab in Medical Technology
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab
(Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) bre...
Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Data Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit Incidence
HAYWARD, Calif., June 3 /PRNewswire-FirstCall/ -- Kosan Biosciences
Incorporated (Nasdaq: KOSN ) today announced that its lead Hsp90 inhibitor,
tanespimycin, demonstrated a high lev...
First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
Collaborative groups set out to confirm potential benefits of anticancer therapies to treat women with breast cancer
PARIS, May 27 /PRNewswire/ -- A new international study for women with
HER2-positive breast cancer is open for enrollment. The pivotal BETH
(BEvacizumab and Trastuz...
Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
...e-free survival of close to 90 percent even in
the absence of (neo)adjuvant trastuzumab
(Herceptin(R)) and chemotherapy.
Additionally, in a subgroup of highly endo...ChemoTherapy) to determine the prospects of
withholding chemotherapy and/or trastuzumab
in HER2+, MammaPrint(R) low risk
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
...ment options to fight this devastating
disease at all stages," he added.
Presentation of Data
Gianni L et al Neoadjuvant trastuzumab
in patients with Friday 12th,
HER2-positive locally advanced breast December
cancer: primary efficacy a...
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
...1 (everolimus) in combination with vinorelbine and trastuzumab
in HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab
( SABCS Abstract #406: Friday, December 12, 2008;...rolimus) in combination with weekly paclitaxel and trastuzumab
in patients with HER-2-overexpressing metastatic b...
Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
...reast cancer death in patients who were determined to be HER2-positive
by Oncotype DX. Since patients in both these studies did not have the
option of trastuzumab
treatment, the direct relationship between HER2 and
Trastuzumab treatment response could not be assessed.
"During tumor sample preparation for IHC o...
US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
...tudied lapatanib (L) alone
and in combination with trastuzumab
(T) in patients with HER2+ metastatic
first to demonstrate the synergy of lapatanib and trastuzumab
in a Phase
The research found that ...
"More complete HER2 blockade with lapatinib and trastuzumab
patients whose metastatic breast cancer (...
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
...o Phase I trials in which
RAD001 was combined with trastuzumab
(Herceptin(R)) and chemotherapy agents
suggest tha...hibitor of mTOR, acts on the pathway that mediates trastuzumab
and has the potential to help restore r... mg/m2, IV over 10-15 min on days 1 and 8 q3w)
(4 mg/kg loading dose, IV over 90 min on day 1 [if...
New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
... received a median of
five prior metastatic breast cancer therapies (range, 0-15) and 28 out of
32 patients enrolled had received prior treatment with trastuzumab
duration 19.7 months). The dosing regimen for this study was 1500 mg of
TYKERB administered orally daily and 10 mg/kg bevacizumab IV every two...
Trastuzumab in Biological News
Vaccine against HER2-positive breast cancer offers complete protection in lab
...tors than is typical, promoting a particularly aggressive type of tumor that affects 20 to 30 percent of all breast cancer patients. Therapies such as trastuzumab
and lapatinib, designed to latch on to these receptors and destroy them, are a mainstay of treatment for this cancer, but a significant proportion of ...
Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
...chemotherapy regimen before surgery, together with trastuzumab
(Herceptin) before and after surgery, according to...blems. These results are very challenging, as both trastuzumab
and anthracyclines are associated with cardiac tox...s trastuzumab, but we wanted to expose patients to trastuzumab
for as long as possible before surgery to make it ...
New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
...advanced breast cancer in which the gene HER-2 was over-expressed. The patients received lapatinib for six weeks, followed by a combination of weekly trastuzumab
and three-weekly docetaxel, given over 12 weeks, before primary surgery. Biopsies were performed at the time of diagnosis and also after six weeks of...
Biomarkers allow doctors to match therapy to patient
...ificant for the greater than 50 percent of breast cancer patients whose tumors fall into the HER2 low-expressing category and who are not eligible for trastuzumab
treatment, Benavides concludes.
Overexpression of ODC1 is associated with poor outcome in childhood neuroblastoma and represents an impo...
A search for protection against chemotherapy cardiotoxicity
...ute cardiotoxic effects induced by doxorubicin and trastuzumab
exposures. The research article describing this wo...f chemotherapeutic agents such as anthracycline or trastuzumab
in oncology is limited by their cardiac toxicity. ...se effects.
The increasing use of doxorubicin and trastuzumab
in adjuvant breast cancer therapy and the growing ...
Other patients bear the real cost of Herceptin
... to balance the books, say doctors in this week’s BMJ.
New guidance from the National Institute for health and Clinical Excellence (NICE) recommends trastuzumab
(Herceptin) in early breast cancer, but it provides no extra funding and does not suggest what cuts should be made to release this extra money. This l...
Analysis of breast-cancer gene role offers promising target
...ncer with drugs that block both HER-2 and urokinase given together."
The study opens a promising avenue to increase the effectiveness of the drug trastuzumab
(Herceptin) by adding a second drug seeking to neutralize the uPAR gene.
"One major avenue of investigation would be to develop an antibody that ...
Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
...axel with the addition of bevacizumab.
Patients whose tumors overexpressed HER-2 were not included in the study unless they had previously received trastuzumab
(Herceptin? or were unable to receive trastuzumab. Also excluded were patients who had received preventive chemotherapy treatment with paclitaxel with...
Trastuzumab in Biological Technology
Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
...rican Cancer Society.
"Patients with triple negative breast cancer do not benefit from endocrine therapy or molecularly targeted therapy such as trastuzumab
because they lack the targets for these drugs," said Dr. Binh Nguyen, M.D., Ph.D., Chief Medical Officer of Tigris. "The potential of using molecular ...
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
...e current standard of care, paclitaxel (Taxol) and trastuzumab
(Herceptin(R)), vs. paclitaxel and trastuzumab
alone. Progression-free survival (PFS) is the pri.... Results showed that Myocet, in combination with trastuzumab
and paclitaxel treatment, yielded an unusually hig...
Sopherion Therapeutics Secures $55 Million in Series C Funding
...registrational trial of Myocet in combination with trastuzumab
and paclitaxel vs. trastuzumab
and paclitaxel for first-line therapy of patients ...vanced breast cancer when used in combination with trastuzumab
and paclitaxel," said Ronald H. Goldfarb, Ph.D., P...
Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
...t that Myocet(R), in combination with the approved trastuzumab
(Herceptin(R)) plus paclitaxel (Taxol) treatment r...nonpegylated liposomal doxorubicin, paclitaxel and trastuzumab
in patients with HER-2-overexpressing locally adva... fraction (LVEF) > 50 percent - received weekly trastuzumab
in combination with escalating doses of weekly pac...
Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
...utical portfolio is focused on three 'biosimilar'
versions of the proteins currently constituting a $15 B market: Insulin,
Etanercept (Enbrel(R)), and trastuzumab
(Herceptin(R)). Our lead
pharmaceutical product, Insulin, targets the US$7.5 billion Insulin market.
NOMAD's Insulin will provide an economical altern...
MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
...l 15 from 1:00 - 5:00 p.m. in Exhibit Hall B-F.
-- IPI-504, a Selective Hsp90 Inhibitor is Biologically Active and Tolerated in Combination with trastuzumab
in Preclinical Models of HER2 Positive Tumor Xenografts (Poster Session: Drug Discovery 2: Combination Strategies I, abstract 4008, poster sec...
Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
...HER2 and HER2:HER2 homodimers, as measured by HERmark, correlate with
clinical outcomes following treatment with the HER2-directed monoclonal
(Herceptin(R), Genentech), suggesting that the assay
can stratify patients with breast cancer according to their degree of
susceptibility to the drug....
Kosan Announces February 28, 2008 Conference Call and Webcast
...h multiple myeloma in a clinical program called TIME.
Tanespimycin is also being studied in HER2-positive metastatic breast
cancer in combination with trastuzumab
(Herceptin(R)). Intravenous and oral
formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin
(KOS-1022), are being evaluated in Phase ...
GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
...s with advanced or metastatic breast
cancer whose tumors overexpress HER2 and who have received prior therapy
including an anthracycline, a taxane and trastuzumab
Additional studies are underway to learn the full potential of TYKERB for
the prevention and treatment of brain metastases.
Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
when administered in combination with trastuzumab
patients whose disease progresse...ter titled, "Tanespimycin (an Hsp90 Inhibitor) and trastuzumab
an Active Combination in Patients (Pts) with HE...ths following last dose of adjuvant
treatment with trastuzumab
or have progressive disease following initial